Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CERo Therapeutics Holdings ( (CERO) ) has shared an update.
On September 22, 2025, CERo Therapeutics Holdings updated its corporate presentation, highlighting its advancements in the biotechnology sector. The presentation detailed the company’s innovative CER-T platform and outlined upcoming clinical trials for its cancer treatments. This update is expected to bolster CERo’s position in the industry by demonstrating its commitment to advancing cancer therapies, potentially impacting investor confidence and market dynamics.
The most recent analyst rating on (CERO) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on the development of novel therapeutic approaches. The company is known for its Chimeric Engulfment Receptor T cells (CER-T) platform, which integrates both innate and adaptive immunity to target and eliminate tumors. CERo’s market focus includes treatments for various cancers, including Acute Myeloid Leukemia, Ovarian, and Non-Small Cell Lung Cancer.
Average Trading Volume: 210,521
Technical Sentiment Signal: Sell
Current Market Cap: $6.51M
For detailed information about CERO stock, go to TipRanks’ Stock Analysis page.